Table 2 Anticancer activity (IC₅₀ ± SD (µM)) of all the synthesized compounds

7a

Cl

Cl

H

hydrazine

 > 200

 > 200

 > 200

ND

7b

Cl

Cl

4-F

hydrazine

 > 200

52.05 ± 4.17

80.05 ± 9.89

73.70 ± 2.40

7c

Cl

Cl

4-Cl

hydrazine

 > 200

 > 200

25.85 ± 1.20

48.55 ± 8.41

7d

Cl

Cl

H

hydroxyurea

 > 200

 > 200

45.10 ± 1.97

ND

7e

Cl

Cl

4-Cl

hydroxyurea

 > 200

 > 200

 > 200

ND

7f

Cl

Cl

H

dimethylurea

 > 200

 > 200

 > 200

38.25 ± 3.18

7g

Cl

Cl

H

p-tolylhydrazine

 > 200

131.90 ± 5.09

 > 200

ND

7h

Cl

Cl

H

(3-chlorophenyl) hydrazine

 > 200

 > 200

 > 200

ND

7i

Br

H

H

hydrazine

46.35 ± 4.03

136.25 ± 1.76

53.5 ± 0.70

102.5 ± 7.07

7j

Br

H

4-F

hydrazine

10.01 ± 5.5

14.65 ± 5.44

63.85 ± 6.57

 > 200

7k

Br

H

4-Cl

hydrazine

12.84 ± 0.84

10.90 ± 0.84

79.25 ± 5.30

19.70 ± 8.06

7l

Br

H

H

hydroxyurea

29.60 ± 2.26

 > 200

28.00 ± 9.89

121.65 ± 11.52

7m

Br

H

H

dimethylurea

108.75 ± 5.30

 > 200

31.08 ± 3.25

ND

7n

Br

H

H

p-tolylhydrazine

 > 200

85.35 ± 0.63

17.40 ± 1.41

14.85 ± 1.90

7o

Br

H

4-Cl

(3-chlorophenyl) hydrazine

165.65 ± 6.85

69.50 ± 7.77

 > 200

26.75 ± 0.35

Cisplatin

–

–

–

–

9.90 ± 0.27

15.25 ± 1.1

–

–

Erlotinib

–

–

–

–

39.30 ± 1.13

11.18 ± 0.38

–

–